You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》兆科眼科(06622.HK)今日起招股 一手入場費8,484.65元
阿思達克 04-16 09:35
由李氏大藥廠(00950.HK)分拆的眼科製藥公司兆科眼科(06622.HK)公布招股詳情,計劃發行約1.24億股股份,當中10%於本港公開發售。由今日(16日)至下周三公開招股,每股招股價介乎15.38元至16.8元,一手500股,入場費為8,484.65元,預計於4月29日上市。高盛及Jefferies為聯席保薦人。

兆科眼科為上市引入八名基石投資者,包括CaaS Capital、新加坡政府投資公司、奧博資本、Golden Valley、Jennison、Mass Ave、VMS Investment、Matthews International Capital Management,合共認購總值5,500萬美元的股份。

以招股價中位數16.09元計,集資淨額為18.58億元,當中約32%用於集團由25種候選藥物組成的龐大管線中兩種核心產品的臨床開發及商業化;46%用於為其他在研候選藥物的持續研發活動及商業化提供資金;7%用於南沙的先進生產設施進行生產線擴張;5%用於為業務開發活動及在研藥物的擴展提供資金;餘下10%將用作營運資金及其他一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account